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Abstract
Studies validating the prognostic accuracy of the tumor-node-metastases (TNM) classification in patients with lung cancer
treated by neoadjuvant therapy are scarce. Tumor regression, particularly major pathological response (MPR), is an
acknowledged prognostic factor in this setting. We aimed to validate a novel combined prognostic score. This retrospective
single-center study was conducted on 117 consecutive patients with non-small cell lung cancer resected after neoadjuvant
treatment at a Swiss University Cancer Center between 2000 and 2016. All cases were clinicopathologically re-evaluated.
We assessed the prognostic performance of a novel prognostic score (PRSC) combining T-category, lymph node status, and
MPR, in comparison with the eighth edition of the TNM classification (TNM8), the size adapted TNM8 as proposed by the
International Association for the Study of Lung Cancer (IASLC) and MPR alone. The isolated ypT-category and the
combined TNM8 stages accurately differentiated overall survival (OS, stage p= 0.004) and disease-free survival (DFS,
stage p= 0.018). Tumor regression had a prognostic impact. Optimal cut-offs for MPR emerged as 65% for adenocarcinoma
and 10% for non-adenocarcinoma and were statistically significant for survival (OS p= 0.006, DFS p < 0.001). The PRSC
differentiated between three prognostic groups (OS and DFS p < 0.001), and was superior compared to the stratification
using MPR alone or the TNM8 systems, visualized by lower Akaike (AIC) and Bayesian information criterion (BIC) values.
In the multivariate analyses, stage III tumors (HR 4.956, p= 0.003), tumors without MPR (HR 2.432, p= 0.015), and PRSC
high-risk tumors (HR 5.692, p < 0.001) had significantly increased risks of occurring death. In conclusion, we support 65%
as the optimal cut-off for MPR in adenocarcinomas. TNM8 and MPR were comparable regarding their prognostic
significance. The novel prognostic score performed distinctly better regarding OS and DFS.
Introduction
Lung cancer is one of the most frequent cancers worldwide
and the leading cause of cancer-related death [1].
Approximately 80% of lung cancer patients are diagnosed
with non-small cell lung cancer (NSCLC). One-third of
them present at a locally advanced stage. This is a hetero-
geneous group for which treatment modalities encompass
multimodal approaches [2]. In resectable locally advanced
NSCLC, neoadjuvant chemotherapy is an important strat-
egy, despite the lack of a clear benefit over adjuvant che-
motherapy with respect to overall survival (OS) [3].
However, it is beneficial regarding three major points,
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comprising (a) consistent chemotherapy delivery for
patients potentially not fit enough for adjuvant chemother-
apy after surgery, (b) biological stress test for the tumor, and
(c) avoidance of futile surgery [4]. Currently, there are no
uniformly defined standards for neoadjuvant chemotherapy
but it usually consists of platinum-based chemotherapy
administered in four cycles [5]. Recently and based on the
success of immunotherapy in the palliative setting, several
studies tested antibodies blocking the programmed cell
death protein 1 (PD1)/programmed cell death 1 ligand 1
(PD-L1) axis in the neoadjuvant setting, either as mono-
therapy or in combination with ipilimumab or chemother-
apy. Especially the combination therapies reached
promising major pathological response (MPR) rates of up to
85% [6]. In contrast, the use of tyrosine kinase inhibitors
(TKI) and molecular-guided perioperative treatment is less
clear and requires further investigation. For example,
response rates to EGFR-targeting TKIs in the neoadjuvant
setting seem lower than in patients with the advanced-stage
disease [7]. Even though additional radiotherapy seems to
improve local tumor control, long-term survival is not
altered presumably because distant micrometastases are not
reached [3].
Different prognostic models have been developed for
locally advanced NSCLC, based on clinical and pathological
parameters [8, 9]. However, only a limited number of patients
receiving neoadjuvant treatment were included [8–10]. To our
knowledge, there are no models explicitly designed for
NSCLC resected after neoadjuvant treatment, though different
clinicopathological parameters have been shown to sig-
nificantly impact survival [11–13]. The amount of residual
tumor is one important parameter [3, 14, 15]. Junker et al.
described a favorable prognosis for patients with low per-
centages of residual tumor and the best prognosis in patients
with a complete pathological response (pCR), i.e. no remnants
of tumor cells in the resected tissue [14]. More recently, Patear
et al. confirmed these results and proposed MPR, defined as
≤10% residual tumor cells, as a more practical marker due to
only limited numbers of cases achieving pCR [15]. As for
other solid tumors, tumor regression could be used as a sur-
rogate marker in neoadjuvant studies and should be included
in pathological reports [3, 16, 17].
In general, the UICC/AJCC tumor-node-metastases
(TNM) classification remains the gold standard to predict
cancer prognosis, but the dataset informing the current
edition has explicitly excluded cases resected after neoad-
juvant therapy, as have most validation studies [18–22]. The
prognosis of patients with locally advanced NSCLC is
dismal and the benefit from neoadjuvant chemotherapy is
limited with only 5% benefit on 5-year OS [23]. In order to
test and advance new therapeutic strategies in a more
selective way, it is crucial to more accurately predict sur-
vival after neoadjuvant therapy using a practical approach.
In this study, we aimed to validate the current eighth
edition of the UICC/AJCC TNM classification (TNM8)
[18] juxtaposed with regression grading in a cohort of
NSCLC resected after a neoadjuvant chemo- or radio-
chemotherapy. We investigated the benefit of adjusting the
tumor size informing the T-category as advocated by the
IASLC and additionally propose a prognostic score with
better stratification combining T-category, lymph node
status, and tumor regression [16].
Patients and methods
Patient cohort
This retrospective single-center study was conducted on a
cohort of consecutive patients with non-neuroendocrine
NSCLCs after neoadjuvant treatment resected between
January 2000 and December 2016 in the department of
general thoracic surgery of the Inselspital Bern and diag-
nosed at the Institute of Pathology, University of Bern. The
cohort was assembled using pathology files and was sub-
sequently validated using the clinical files of the Inselspital
Bern, the survival data by the cantonal cancer registry, and
contacting general practitioners [24, 25].
This study was conducted according to the REMARK-
criteria and approved by the Cantonal Ethics Commission
of the Canton of Bern (KEK 2017-00830), which waived
the requirement for written informed consent [26].
To guarantee neoadjuvant intention, only patients who
had received at least 1 cycle of platinum-based che-
motherapy were eligible for inclusion. Unclear cases were
re-evaluated by consulting an experienced oncologist (AS).
Initially, the cohort comprised 129 cases. After re-
evaluation of the clinical files, ten patients were excluded
due to lack of neoadjuvant intention of the therapy prior to
resection and two patients due to missing material for
appropriate evaluation of tumor regression. Finally, 117
cases were included in the study cohort (Supplementary
Fig. S-1). There were 85 (73%) men and 32 (27%) women.
The median age at surgery was 62 years (IQR 56–69).
Detailed baseline characteristics are presented in Table 1.
The neoadjuvant regimen was further grouped correspond-
ing to the current standards at the Inselspital Bern. Hence,
64/117 (54.7%) patients received the standard regimen
consisting of at least three cycles of platinum-based che-
motherapy and an additional taxane and 53/117 (45.3%)
received one cycle of platinum-based chemotherapy in
combination with another cytotoxic agent or less than three
cycles. The applied drug combinations are summarized in
Table 1. In two patients the specific regimen was not
reported but neoadjuvant treatment was confirmed by
pathological or clinical documentation. An adaptation of
P. Zens et al.
Table 1 Baseline characteristics of the study cohort according to squamous cell carcinoma and adenocarcinoma histology.
SQCC ADC p-Value Other
(n= 54) (n= 56) (n= 7)
Age, years (median [IQR]) 63[55.25–69.75] 62[55.75–68.25] 0.788a 68[59–71]
Smoking status n= 48 (%) n= 49 (%) 0.193b n= 6 (%)
Non-smoker 3(6.2) 9(18.4) 2(33.3)
Ex-smoker 27(37.5) 22(44.9) 4(66.7)
Active smoker 18(56.2) 18(36.7)
Macroscopic tumor bed, cm (median [IQR]) 3.5[2.58–5.42] 3.5[2.38–4.20] 0.385a 4[1.9–4.35]
Adjusted tumor size, cm (median [IQR]) 1.24[0.06–2.76] 1.78[0.05–2.95] 0.832a 0[0–3.16]
ypT-TNM8 n= 54 (%) n= 56 (%) 0.805a n= 7 (%)
ypT0 6(11.1) 5(8.9) 4(57.1)
ypT1 14(25.9) 19(33.9)
ypT2a 11(20.4) 9(16.1)
ypT2b 3(5.6) 3(5.4) 1(14.3)
ypT3 6(11.1) 13(23.2) 1(14.3)
ypT4 14(25.9) 7(12.5) 1(14.3)
TNM8 n= 54 (%) n= 56 (%) 0.557a n= 7 (%)
No vital tumor 3(5.6) 3(5.4) 4(57.1)
Stage I 10(18.5) 12(21.4)
Stage II 14(25.9) 11(19.7)
Stage III 26(48.1) 26(46.4) 3(42.9)
Stage IV 1(1.9) 4(7.1)
Regression n= 54 (%) n= 56 (%) 0.460a n= 7 (%)
pCR 3(5.6) 4(7.1) 4(57.1)
<1% 9(16.7) 9(16.1)
1–10% 9(16.7) 6(10.7)
11–49% 9(16.7) 6(10.7) 1(14.3)
≥50% 24(44.3) 31(55.4) 2(28.6)
PRSC n= 54 (%) n= 56 (%) 0.332a n= 7 (%)
Low risk 23(42.6) 21(37.5) 4(57.1)
Intermediate risk 14(25.9) 25(44.6) 1(14.3)
High risk 17(31.5) 10(17.9) 2(28.6)
Neoadjuvant chemotherapy n= 53 (%) n= 55 (%) 0.551b n= 7 (%)
Cisplatin+ docetaxel 31(58.5) 31(56.4) 6(85.7)
Carboplatin+ paclitaxel 3(5.7) 2(3.6)
Cisplatin+ pemetrexed 6(11.3) 7(12.7)
Cisplatin+ gemcitabin 6(11.3) 3(5.5)
Cisplatin+ vinorelbin 2(3.8) 7(12.7) 1(14.3)
Cisplatin+ etoposid 1(1.8)
Other 5(9.4) 4(7.3)
Neoadjuvant radiotherapy n= 50 (%) n= 54 (%) 0.689b n= 7 (%)
No 38(76) 38(70.4) 4(57.1)
Yes 12(24) 16(29.6) 3(42.9)
Surgical procedure n= 54 (%) n= 56 (%) 0.001b n= 7 (%)
Lobectomy 23(42.6) 42(75) 4(57.1)
Bilobectomy 4(7.4) 1(1.8)
Pneumonectomy 27(50) 13(23.2) 3(42.9)
R n= 53 (%) n= 55 (%) 0.031b n= 7 (%)
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chemotherapy was reported for 28/117 (23.9%) patients as
adjustment of dose in 12 and change of drug in 16 cases.
Most patients (n= 85) received three cycles of neoadjuvant
chemotherapy and the neoadjuvant regimen was given over
a median of 63 [IQR 62–80.5] days. One patient received a
maximum of 12 cycles over a period of 256 days due to a
change of therapy after bronchospasms. Two patients had to
stop the neoadjuvant therapy after one cycle due to severe
medical conditions (purulent effusion, myocardial infarc-
tion). The tumors were resected after a median of 29 [IQR
15–48] days. One patient received perioperative therapy and
one patient was operated on with a delay of 222 days due to
discontinuation of therapy during the fourth cycle and the
following rehabilitation after pneumonia with subsequent
worsening of the general condition. Adjuvant radio-
chemotherapy was reported in four patients, isolated adju-
vant chemotherapy in five patients, and isolated adjuvant
radiotherapy for 16 patients.
Patients who were lost to follow up or died within 30 days
after surgery were excluded from survival analyses. The
disease-free survival (DFS) was defined as the interval
between the start of treatment and loco-regional or metastatic
recurrence or death from any cause. Relapse was defined as
the clinical diagnosis of tumor recurrence ≥3 months after the
resection. OS was defined as the time elapsed from the start of
treatment to death of any cause. The start of treatment was
defined as the start of neoadjuvant therapy. For three cases the
date of resection was chosen for survival analyses as the dates
of the neoadjuvant chemotherapy were not available but
neoadjuvant treatment was explicitly mentioned in the
pathological or clinical documentation. Survival data for
analyses was restricted to 5 years after surgery due to the
multimorbidity of patients. Survival analyses were possible
for 105 patients after the exclusion of two patients due to
missing survival information and ten patients due to the last
follow-up date within 30 days after surgery. Further five
patients were excluded due to distant metastases. Median OS
was 43 months (95% CI= 32–NA) and 47 events occurred
(Supplementary Fig. S-2). Median DFS was 21 months (95%
CI= 15–29 months) and 68 events occurred (Supplementary
Fig. S-2).
Histological tumor types
Histological tumor type was re-evaluated for each case by
two investigators (SB, PZ) according to the current 2015
World Health Organization criteria [27]. The cohort con-
sisted of 54 (46.1%) squamous cell carcinomas (SQCC), 56
(47.9%) adenocarcinomas, 3 (2.6%) adenosquamous carci-
nomas, and 4 (3.4%) NSCLC not otherwise specified. The
unspecified NSCLC showed pCR in the resection specimen,
without residual tumor cells for immunohistochemical
work-up, and no defined histology in the pathological report
of the biopsies. One patient was diagnosed with an
advanced SQCC decisive for the neoadjuvant treatment and
a small separate adenocarcinoma of 1.5 cm diameter
observed in the resection specimen.
Tumor staging
Staging-parameters were re-evaluated for each case by two
investigators (SB, PZ) accessing all available HE slides,
pathology reports, and clinical files. As pleural invasion is
pT relevant, it was re-assessed by re-evaluating the H&E
slides and if necessary performing elastica-van-Gieson
stains according to standard protocols [28].
All cases were re-staged according to TNM8 [18]. The T
categories were included as size-adapted (respecting the
proportion of residual tumor cells) and non-adapted vari-
ables. The adapted tumor size was reassessed according to
the current IASLC recommendations by multiplying the
vital tumor percentage with the described tumor bed
extracted from the pathology report [16]. In case of missing
H&E slides, sections were recut from the corresponding
paraffin blocks.
Lymph-node stages were validated using the IASLC
lymph node map [29]. Lymph nodes were free of residual
tumor (ypN0) in 50/117 (42.7%) cases. Ipsilateral hilar
lymph nodes were involved (ypN1) in 23/117 (19.7%)
cases, ipsilateral mediastinal lymph nodes (ypN2) in 42/117
(35.9%) cases, and contralateral or supraclavicular lymph
nodes (ypN3) in 2/117 (1.7%) cases. Five patients (4.3%)
had distant metastases at the time of surgery.
Table 1 (continued)
SQCC ADC p-Value Other
(n= 54) (n= 56) (n= 7)
R0 41(77.4) 51(92.7) 7(100)
R1 12(22.6) 4(7.3)
SQCC squamous cell carcinoma, ADC adenocarcinoma, ypT-TNM8 ypT according TNM eighth edition, TNM8 stages according TNM eighth
edition, pCR pathological complete response, PRSC prognostic score.
aMann–Whitney-U test.
bFisher’s exact test.
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Tumor regression grade
Residual tumor content in the background of therapy-
induced fibrosis and necrosis was evaluated by two inves-
tigators (SB, PZ) using a dual-head microscope, re-
evaluating all available tumor material. In the few cases
of discordance, the agreement was reached by consensus
after thorough discussion. Two previous studies have
reported a high reproducibility in the assessment of MPR in
NSCLC [30, 31]. Specimen grossing as retrospectively
evaluated for all tumors was for the majority of cases in line
with the current IASLC guidelines advising complete
inclusion of tumors <3 cm and sampling of at least 1 block
per diameter of the tumor bed [16]. On average, 2.2 paraffin
blocks were submitted per tumor bed diameter (median 2
[range 0.4–8.7]) as detailed in supplementary Table S-1.
There were 14/117 (12%) borderline cases with marginally
<1 block submitted per diameter tumor bed. Only 2 cases
had ~ 0.5 a paraffin block or less submitted per tumor bed
diameter, thus not adhering to the current recommendations.
One case constituted a large carcinoma of 13 cm diameter
with 5% residual tumor and the other one (80% residual
tumor) was associated with considerable retrotumoral
pneumonic remodeling which was not counted as tumor bed
in our re-evaluation.
We assessed tumor regression as continuous variables
using 1% increments till 10% and in 5% increments in cases
showing >10% residual tumor in the primary tumor bed
according to IASLC recommendations to calculate the
adapted tumor size [16].
Regression was dichotomized into cases with and with-
out MPR, currently defined as ≤10% residual tumor
[15, 17]. In addition, histology-adapted MPR was deter-
mined for adenocarcinoma and non-adenocarcinoma cases
separately, setting optimal cut-offs based on the proportion
of residual tumor in the primary lesion to dichotomize
survival using maximally selected rank statistic as described
before [30].
Tumor regression grade (TRG) was assessed
semi-quantitatively as the percentage of residual tumor cells
in the primary tumor and regional lymph nodes using
the following increments: no residual tumor (pCR),
<1%, 1–10%, 11 to <50% and ≥50% residual tumor cells
(Fig. 1) [14].
Prognostic score
MPR, nodal infiltration (ypN), and the T-category (ypT-
TNM8) were combined in a prognostic score (PRSC)
similar to the scores described for gastric and oesophageal
cancers after neoadjuvant treatment [32, 33]. Each factor
was assigned a point value according to the respective
prognostic impact (0 or 1 points each), the sum of which
resulted in stratification into three risk categories: low risk
0–1 point, intermediate-risk 2 points, high risk 3 points
(Table 2, Supplementary Fig. S-3). In line with our results
for histology-adapted MPR (see below), we investigated the
PRSC using the MPR cut-off of 10% and a histology-
adapted PRSC adapting for different MPR cut-offs, using
10% in non-adenocarcinomas and 65% in adenocarcinomas.
Statistical analyses
All analyses were performed using R software (version
3.6.3, https://cran.r-project.org) with suitable packages.
Association between variables was assessed using Fisher’s
exact test for nominal variables and Mann–Witney-U,
Kruskal–Wallis tests for ordinal variables. For the correla-
tion between ordinal or numerical variables, we used the
rank correlation according to spearman. The maximally
selected rank statistics were used for the selection of sui-
table cut-offs applying log-rank scores as the test statistic
and approximated p-values according to Hothorn and
Lausen [34]. Kaplan–Meier plots were used to visualize
survival data with the corresponding p-values according to
the log-rank test. Cox proportional hazard models were used








Fig. 1 Representative H&E slides for estimation of the residual
tumor. Light-blue: demarcation of tumor tissue, Yellow: demarcation
of necrosis, Green: demarcation of cholesterol crystals, Red: demar-
cation of thickened/hyalinized vessels, Black: demarcation between
tumor/necrosis.
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for univariate and multivariate analyses. Univariate pre-
dictors were included in the multivariate model at p ≤ 0.1.
The Akaike information criterion (AIC) and Bayesian
information criterion (BIC) were used to compare the
goodness-of-fit between the different prognostic models.
This method adjusts the −2 log-likelihood statistics for the
number of parameters in the model and the number of
observations used. Smaller AIC and BIC indicate superior
model fit with the probability of a better fit being pi. The
level of significance was set at a two-sided p= 0.05.
Results
Stage migration due to size adjustment for ypT
We evaluated the migration of ypT and tumor stage after
adjusting for the residual tumor in the primary tumor bed
(Supplementary Table S-2). In summary, 27/117 (23.1%)
cases migrated to a lower ypT category (not including chan-
ges within ypT1). This resulted in an adapted TNM stage in
only 16/117 (13.7%) cases (Supplementary Table S-3).
In detail, a total of 10/117 (8.5%) node-negative cases
were downstaged to stage I A 1 (ypT1b [n= 4], ypT1c
[n= 3], ypT2a [n= 2], ypT2b [n= 1] to ypT1a). Two
(1.7%) node-negative cases were downstaged to stage I A 2
(ypT2a [n= 1] and ypT3 [n= 1] to ypT1b). One (0.9%)
node-negative case was downstaged to stage I A 3 (ypT2a
to ypT1c). Three (2.6%) node-negative cases changed to
stage I B (ypT2b [n= 1], ypT3 [n= 1], ypT4 [n= 1] to
ypT2a). One (0.9%) case with positive hilar lymph nodes
was downstaged to stage II B (ypT3 to ypT1b). Two (1.7%)
node-negative cases were downstaged to stage II B due to a
change from ypT4 to ypT3. Two (1.7%) cases with positive
mediastinal lymph nodes were downstaged to III A due to a
change from ypT3 to ypT2b. Two (1.7%) cases with ypT4
were downstaged from stage III B to stage III A due to
migration to ypT1b and ypT2b.
Prognostic value of TNM8
Both the adapted and non-adapted TNM8 were sig-
nificantly associated with survival regarding the ypT-
category or the tumor stage and OS or DFS. Figure 2 dis-
plays the survival curves for the non-adapted TNM8
(OS ypT p < 0.001 Fig. S-4A, stage p= 0.004 and
DFS ypT p < 0.001 Fig. S-4C, stage p= 0.018).
Supplementary Figs. 4B–D and 5 display the survi-
val curves for the adapted TNM8 (OS ypT
p < 0.001, stage p= 0.013 and DFS ypT p= 0.003, stage
p= 0.025). The categories ypT2b and a pCR (=stage 0) had
worse OS and DFS than the corresponding higher cate-
gories. This is most probably due to the small number of
patients in these categories. Only three patients were staged
ypT2b after size adjustment, two of which were downstaged
from ypT3. Six patients with non-adapted ypT-categories
were staged ypT2b, of whom two showed tumor progres-
sion after surgery and all others relapsed within 17 months
after resection. Five of the nine cases with pCR died within
the 5-year follow-up time, of which three patients relapsed
and one patient was diagnosed with multiple myeloma
4 months prior to death. The AIC and BIC scores of the
adapted TNM8 scoring system are higher compared to the
original TNM8 indicating a worse fit (Table 3). However,
the difference is only marginal and not sufficient to con-
clude a difference of performance between the models.
Tumor regression
Assessing TRG, no residual tumor (defined as pCR) could
be identified in 11/117 (9.4%) cases. Eighteen/117 (15.4%)
cases showed <1%, 15/117 (12.8%) 1–10%, 16/117
(13.7%) 11–49% and 57/117 (48.7%) ≥50% residual tumor.
pCR in the primary tumor bed was observed in 15 (12.8%)
cases of which 4 cases had tumor-infiltrated lymph nodes
with little pathologic regression considered to show in total
<1% residual tumor. One case had a clinically diagnosed
metastasis in the adrenal gland without available histolo-
gical samples (regarded as pCR due to favorable follow-up
data). Higher TRG correlated with lower TNM categories
(ypT p < 0.001, ypN p < 0.001, stage p < 0.001 after
exclusion of cases with pCR) and was associated with
additional neoadjuvant radiotherapy (p < 0.001).
A median of 40% [IQR 0.5–80] residual tumor cells was
detected in the primary lesion. For the entire cohort, we
determined the most accurate cut-off for MPR at 10%
residual tumor. A total of 44/117 (37.6%) cases presented
≤10% residual tumor, defining MPR. MPR correlated with
lower TNM categories (ypT p < 0.001, ypN p < 0.001, stage
p < 0.001 after exclusion of cases with pCR) and was
associated with neoadjuvant radiochemotherapy (p < 0.001)
and R0 status (p= 0.023).




Parameter 0 points 1 point 0 points 1 point
ypT-TNM8 ≤ypT2a >ypT2a ≤ypT2a >ypT2a
ypN-TNM8 ypN0 ypN1-3 ypN0 ypN1-3
Residual Tumor ≤10% >10% ≤10%a/≤65%b >10%a/>65%b
Scoring: 0–1 points, low risk; 2 points, intermediate risk; 3 points,
high risk.
ypT-TNM8 ypT according TNM eighth edition, ypN-TNM8 ypN
according TNM eighth edition.
aNon-adenocarcinoma.
bAdenocarcinoma.
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Tumor regression—histology-adapted percentage
for MPR
In addition, we explored if divergent cut-offs would be
preferable for different histological tumor types. The opti-
mal cut-off was 65% residual tumor for adenocarcinomas
and 9% residual tumor for SQCC. Histology adapted MPR
was therefore set at ≤65% residual tumor for adenocarci-
nomas, representing 2/3, and ≤10% residual tumor for non-
adenocarcinoma cases, resulting in 53/117 (45.3%) cases
with adapted MPR. Adapted MPR correlated with lower
TNM categories (ypT p < 0.001, ypN p < 0.001, stage
p < 0.001 after exclusion of cases with pCR) and was
associated with neoadjuvant radiochemotherapy (p= 0.001)
and R0 status (p= 0.019).
Prognostic value of tumor regression
Lower tumor regression was statistically significantly
associated with shorter survival (OS p= 0.04 and DFS
p= 0.02), with increasing HR per proportion of residual
tumor for OS (HR 1.008 95% CI 1.000–1.015) and DFS
(HR 1.007 95% CI 1.001–1.013). TRG was significantly
associated with DFS (p= 0.006) but failed to show a sig-
nificant association with OS (p= 0.091).
A dichotomized evaluation using the 10% cut-off for
MPR regardless of histological tumor type resulted in a
statistically significant stratification for OS (p= 0.01, HR of
2.368 95% CI 1.203–4.663, Fig. 3A), and DFS (p < 0.001,
HR 2.548 95% CI 1.461–4.443, Fig. 3C). In adenocarci-
nomas, adapted MPR had a significant impact on DFS
(p= 0.027), but not on OS (p= 0.4, Supplementary Fig. S-
6), presumably due to low sample size (n= 45). In non-
adenocarcinoma cases, adapted MPR had a significant
impact on OS (p= 0.01) and DFS (p= 0.013) with 55 cases
included (Supplementary Fig. S-6). A dichotomized eva-
luation of the entire cohort using the adapted MPR had a
highly significant impact on both OS (p= 0.006) and DFS
(p < 0.001) and resulted in similar HR as when using the
non-adapted MPR (Fig. 3B–D).
Prognostic value of the prognostic score
The PRSC discriminated between three risk groups
(Table 3): 48/117 (41%) patients were in the low-risk group,
41/117 (35%) patients in the intermediate and 28/117 (24%)
in the high-risk group. PRSC risk groups showed an overall
significant difference for OS (p < 0.001, Fig. 3E) with a
significantly higher risk of death for patients in the high-risk
group (HR 6.010 95% CI 2.8361–12.7400). For the low-
risk group, the median OS was not reached. The
intermediate-risk group had a median OS of 43 months
(95% CI 28–NA) and the high-risk group a median OS of























































































5−year Disease−free Survival accoding to TNM8 stage
Fig. 2 Survival according to TNM staging. Kaplan-Meier curves depicting 5-year overall survival (A) and 5-year disease-free survival (B)
according to TNM (8th edition).
Table 3 Comparison of
goodness-of-fit criteria between
the applied prognostic models.
TNM8 Adapted TNM8 MPR Adapted MPR PRSC Adapted PRSC
df 3 3 1 1 2 2
OS
AIC 382.4417 385.5961 385.7463 385.1203 372.9114 372.9499
BIC 387.9922 391.1465 387.5965 386.9705 376.6117 376.6502
DFS
AIC 543.2423 544.0249 537.7455 538.2779 534.3239 532.7202
BIC 549.9009 550.6834 539.965 540.4974 538.7629 537.1592
TNM8 stages according TNM 8th edition, MPR major pathological response, PRSC prognostic score, df
degrees of freedom, OS overall survival, DFS disease-free survival, AIC Akaike information criterion, BIC
Bayesian information criterion.
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median DFS of 45 months (95% CI 28–NA), the
intermediate-risk group a median DFS of 16 months (95%
CI 10–25), and the high-risk group a median DFS of
9.5 months (95% CI 7–26). The overall difference in DFS
was significant (p < 0.001, Fig. 3G), and patients at inter-
mediate risk (HR 2.2110 95% CI 1.2410–3.9380) and high
risk (HR 3.7940 95% CI 2.0180–7.1350) had a significantly
higher risk for death or recurrence.
The histology adapted PRSC using adapted MPR cut-
offs resulted in the migration of two adenocarcinomas from
the intermediate to the low-risk group. Overall, the strati-
fication had a statistically significant impact on survival (OS
p < 0.001, DFS p < 0.001, Fig. 3F–H) and the HR was
comparable to the non-adapted PRSC.
Multivariate analyses
Multivariate analyses were conducted separately for MPR/
adapted MPR, TNM8 stages/adapted stages, and the PRSC/
adapted PRSC as these parameters were significantly
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5−year Disease−free Survival accoding to adapted prognostic score
Fig. 3 Survival according to tumor-response to neoadjuvant therapy assessed by different scoring systems. Kaplan–Meier curves depicting
5-year overall survival (A, B, E, F) and 5-year disease-free survival (C, D, G, H) according to non-adapted MPR (A)–(C) or prognostic score (E)–
(G) and adapted MPR (B)–(D) or prognostic score (F–H).
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associated with each other. Table 4 represents the final
multivariate models of non-adapted prognostic markers
including only parameters without any association to stage,
MPR or PRSC.
Non-adapted and adapted MPR were significant prog-
nostic predictors for OS independently of a change in
neoadjuvant chemotherapy or conducted surgical
procedure.
Due to the small sample size of cases with pCR, only
stages I–III were included in the multivariate model. Stage
III patients of the non-adapted and adapted TNM8 staging
system had a significantly higher risk for death irrespective
of a change in neoadjuvant chemotherapy.
For the non-adapted PRSC, patients of the high-risk
group had worse OS independent of a change in neoadju-
vant chemotherapy or conducted surgical procedure. For the
adapted PRSC, patients of the intermediate- or high-risk
group had worse OS independent of a change in neoadju-
vant chemotherapy.
Comparison between the different prognostic
models
The PRSC model, both using the histology adapted cut-offs
and the 10% cut-off regardless of histology, was superior
compared to the stratification using MPR alone or the
TNM8 systems, visualized by lower AIC and BIC values
(Table 3). The probability of the non-adapted TNM8 system
to better predict OS (pTNM= 0.8%) or DFS (pTNM= 1.2%)
compared to the PRSC was below 5%.
Discussion
The present study compares the prognostic significance of
the TNM8 system, tumor regression grading and a com-
bined PRSC in a clinicopathological well-annotated single-
center retrospective cohort of NSCLC resected after
neoadjuvant treatment.
The UICC/AJCC TNM classification remains the
guideline of choice to predict prognosis in patients with
NSCLC. However, most of the validation studies explicitly
excluded patients with neoadjuvant treatment regimens, and
additional studies are needed to apply and confirm the
IASLC-recommended yT-adjustment after neoadjuvant
therapy [16, 19–21]. In our cohort, the integration of
regression in the yT-category alone did not yield a better
fitting prognostic model compared to the original
TNM8 system. Only 16 (13.7%) cases were downstaged
due to adaptation of tumor size according to the current
IASLC recommendations [16]. This could be explained by
a high proportion of cases with ≥50% of residual tumor after
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We confirm the prognostic significance of MPR in
NSCLC. These results are in line with existing literature
propagating MPR as a possible surrogate endpoint in
neoadjuvant trials [3, 15, 17]. In concordance with Qu and
colleagues, we support the assessment of residual tumor in
steps of 5–10% and confirm 65% as the optimal cut-off for
assessing MPR in adenocarcinomas. Our findings support
the adaptation of MPR according to the histologic tumor
type [30, 35, 36].
Compared to the classic TNM8 system, the MPR model
performed comparable regarding OS but was superior
regarding DFS. The strong association of MPR and additional
neoadjuvant radiotherapy may provide a possible explanation.
In most of the previous reports on tumor regression after
neoadjuvant radiochemotherapy, the fraction of cases
achieving MPR was higher compared to studies including
only patients after neoadjuvant chemotherapy [13, 35, 37–41].
Among our cases eligible for survival analyses, only 36
(36%) showed MPR corresponding to 64.3% of the group
receiving neoadjuvant radiochemotherapy and 26.5% of the
group receiving neoadjuvant chemotherapy. Neoadjuvant
radiochemotherapy seems to result in better loco-regional
control of the tumor and higher rates of complete resection,
thus prolonging the time to recurrent disease [3, 42].
The combination of multiple parameters into a prognostic
score in order to better stratify patients has already been
suggested for locally advanced primary resected NSCLC
[8, 9]. Liang et al. established a prognostic nomogram com-
bining age, histology, number of sampled lymph nodes,
gender, T-category, and N-category predicting OS more
accurately than the TNM staging system [9]. Pilotto et al.
developed a score for SQCC combining age, T-category,
nodal status, and tumor grading [8]. This group was able to
validate their model in a multicentric retrospective cohort and
showed the prognostic impact of adjuvant or neoadjuvant
therapy in the intermediate and high-risk groups using pro-
pensity score analyses [10]. However, including tumor grad-
ing into prognostic scores is problematic, as (a) grading
should not be assessed after neoadjuvant therapy due to
therapy-induced morphological changes and (b) despite
widely used propositions e.g., for adenocarcinoma of the
lung, there are to date no universally accepted grading sys-
tems for NSCLC [27]. In addition, a simpler model for routine
clinical application is necessary. For gastric and oesophageal
cancers, such combined scores have demonstrated a superior
accuracy compared to the classic TNM staging system, but to
our knowledge, no such combined scores exist for NSCLC
after neoadjuvant treatment [32, 33]. We constructed a
prognostic score integrating the same components: T-cate-
gory, nodal status, and MPR. This model showed superior
prognostic accuracy over the TNM staging system even after
adapting for tumor size (T-category) according to residual
tumor in the primary tumor bed.
The strength of our study is the complete clin-
icopathological re-validation of the cohort including
homogenization of stage and tumor type according to cur-
rent guidelines and integration of the recommendations of
the IASLC, thereby including information on tumor
regression in the TNM stages [16]. The limitation of our
study is inherent in the study design using a real-life cohort,
thus the therapeutic regimens had been adapted to the needs
of the patients. This becomes obvious regarding the vast
range of administered cycles of chemotherapy and the
varying time intervals between neoadjuvant therapy and
surgery. However, the time intervals had no significant
prognostic impact as assessed by univariate cox-regression
analysis. Using a real-life cohort resected during a large
time-frame of 16 years resulted also in the lack of a stan-
dardized grossing procedure. Even though, we deem our
results have not been substantially biased. Only 2 out of 117
cases were insufficiently sampled according to current
IASLC guidelines [16]. Both cases were squamous cell
carcinomas and showed 80% respectively 5% residual
tumor in the primary lesion.
Our sample size is comparable to other retrospective
cohorts investigating potential survival predictors in
NSCLC after neoadjuvant treatment and the role of tumor
regression: Pöttgen et al. (n= 157), Remark et al. (n= 122),
Betticher et al. (n= 75) or Pataer et al. (n= 192)
[13, 15, 37, 43].
In conclusion, we were able to demonstrate the prognostic
validity of the TNM8 classification, both using sizes adapted
and non-adapted T-category, in a cohort of curatively resected
NSCLC after neoadjuvant treatment. Since the prognosticat-
ing performance was considerably increased by integrating
the non-adapted ypT, nodal status, and MPR into a combined
prognostic score, pathologic tumor response should be
acknowledged as an additional relevant prognostic factor in
NSCLC treated by neoadjuvant therapy.
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